{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T21:39:36Z","timestamp":1785361176686,"version":"3.55.0"},"reference-count":93,"publisher":"SAGE Publications","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dermatitis"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1097\/der.0000000000000803","type":"journal-article","created":{"date-parts":[[2021,12,3]],"date-time":"2021-12-03T11:55:03Z","timestamp":1638532503000},"page":"387-395","source":"Crossref","is-referenced-by-count":7,"title":["An Approach to Hypereosinophilic Syndrome Presenting With Cutaneous Features"],"prefix":"10.1177","volume":"33","author":[{"given":"Kayla","family":"Fourzali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gil","family":"Yosipovitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Maderal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"issue":"3","key":"bib1-20221117","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jaci.2012.02.019","article-title":"Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes","volume":"130","year":"2012","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"bib2-20221117","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/j.jaip.2018.06.002","article-title":"Eosinophil-related disease and the skin","volume":"6","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"10","key":"bib3-20221117","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1002\/ajh.25617","article-title":"World Health Organization\u2013defined eosinophilic disorders: 2019 update on diagnosis, risk stratification, and management","volume":"94","year":"2019","journal-title":"Am J Hematol"},{"issue":"3","key":"bib4-20221117","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.iac.2007.07.001","article-title":"Cardiovascular manifestations of hypereosinophilic syndromes","volume":"27","year":"2007","journal-title":"Immunol Allergy Clin North Am"},{"issue":"5","key":"bib5-20221117","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1111\/j.1365-2141.2008.07294.x","article-title":"Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study","volume":"143","year":"2008","journal-title":"Br J Haematol"},{"issue":"9","key":"bib6-20221117","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.3324\/haematol.11420","article-title":"The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha\u2013positive hypereosinophilic syndrome. Results of a multicenter prospective study","volume":"92","year":"2007","journal-title":"Haematologica"},{"issue":"11","key":"bib7-20221117","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1038\/leu.2012.162","article-title":"Long-term follow-up of FIP1L1-PDGFRA\u2013mutated patients with eosinophilia: survival and clinical outcome","volume":"26","year":"2012","journal-title":"Leukemia"},{"issue":"8","key":"bib8-20221117","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1182\/blood-2011-03-343426","article-title":"Response of ETV6-FLT3\u2013positive myeloid\/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3","volume":"118","year":"2011","journal-title":"Blood"},{"issue":"7","key":"bib9-20221117","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1002\/ajh.25825","article-title":"Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1-JAK2, BCR-JAK2 and ETV6-ABL1 fusion genes","volume":"95","year":"2020","journal-title":"Am J Hematol"},{"issue":"6","key":"bib10-20221117","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/j.jaci.2009.09.022","article-title":"Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy","volume":"124","year":"2009","journal-title":"J Allergy Clin Immunol"},{"issue":"8","key":"bib11-20221117","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.leukres.2008.12.001","article-title":"Success of short-term, higher-dose imatinib mesylate to induce clinical response in FIP1L1-PDGFRalpha\u2013negative hypereosinophilic syndrome","volume":"33","year":"2009","journal-title":"Leuk Res"},{"issue":"8","key":"bib12-20221117","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.jdcr.2019.05.026","article-title":"Lymphocyte-variant hypereosinophilic syndrome presenting as chronic dermatitis and responding to mycophenolic acid","volume":"5","year":"2019","journal-title":"JAAD Case Rep"},{"issue":"10","key":"bib13-20221117","doi-asserted-by":"crossref","first-page":"e232142","DOI":"10.1136\/bcr-2019-232142","article-title":"Hypereosinophilic dermatitis: generalised lichenification and gyrate erythema as the sole manifestation of idiopathic hypereosinophilic syndrome","volume":"12","year":"2019","journal-title":"BMJ Case Rep"},{"issue":"11","key":"bib14-20221117","first-page":"1060","article-title":"Hypereosinophilic dermatitis. An overlooked diagnosis? [in German]","volume":"56","year":"2005","journal-title":"Hautarzt"},{"issue":"5","key":"bib15-20221117","doi-asserted-by":"crossref","first-page":"e210","DOI":"10.1016\/j.jaad.2012.02.043","article-title":"Narrowband UVB therapy for the treatment of pruritus in hypereosinophilic syndrome: clinical report and review of the literature on phototherapy","volume":"67","year":"2012","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"bib16-20221117","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa070812","article-title":"Treatment of patients with the hypereosinophilic syndrome with mepolizumab","volume":"358","year":"2008","journal-title":"N Engl J Med"},{"issue":"6","key":"bib17-20221117","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.jaci.2020.08.037","article-title":"Efficacy and safety of mepolizumab in hypereosinophilic syndrome: a phase III, randomized, placebo-controlled trial","volume":"146","year":"2020","journal-title":"J Allergy Clin Immunol"},{"issue":"8","key":"bib18-20221117","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1182\/blood-2003-10-3620","article-title":"Safety and efficacy of the monoclonal anti\u2013interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome","volume":"103","year":"2004","journal-title":"Blood"},{"issue":"11","key":"bib19-20221117","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1111\/ddg.13926_g","article-title":"Effective treatment of a lymphocytic variant of hypereosinophilic syndrome with reslizumab","volume":"17","year":"2019","journal-title":"J Dtsch Dermatol Ges"},{"issue":"6","key":"bib20-20221117","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.anai.2018.02.017","article-title":"Treatment of hypereosinophilic syndrome and eosinophilic dermatitis with reslizumab","volume":"120","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"14","key":"bib21-20221117","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1056\/NEJMoa1812185","article-title":"Benralizumab for PDGFRA-negative hypereosinophilic syndrome","volume":"380","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"bib22-20221117","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1158\/1078-0432.CCR-08-1302","article-title":"Alemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic leukemia","volume":"15","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"3","key":"bib23-20221117","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.clml.2012.09.018","article-title":"Long-term follow-up of patients with hypereosinophilic syndrome treated with alemtuzumab, an anti-CD52 antibody","volume":"13","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"bib24-20221117","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.jid.2016.10.044","article-title":"Treatment of hypereosinophilic syndrome with cutaneous involvement with the JAK inhibitors tofacitinib and ruxolitinib","volume":"137","year":"2017","journal-title":"J Invest Dermatol"},{"issue":"1","key":"bib25-20221117","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1046\/j.1365-2141.2002.03771.x","article-title":"Successful non-myeloablative allogeneic transplantation for treatment of idiopathic hypereosinophilic syndrome","volume":"119","year":"2002","journal-title":"Br J Haematol"},{"issue":"1","key":"bib26-20221117","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/PRS.0b013e318219c171","article-title":"The levels of evidence and their role in evidence-based medicine","volume":"128","year":"2011","journal-title":"Plast Reconstr Surg"},{"issue":"6","key":"bib28-20221117","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/j.jaip.2017.08.001","article-title":"Biologic agents for the treatment of hypereosinophilic syndromes","volume":"5","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"10","key":"bib29-20221117","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1182\/blood-2004-03-0787","article-title":"FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia","volume":"104","year":"2004","journal-title":"Blood"},{"key":"bib30-20221117","doi-asserted-by":"crossref","first-page":"151412","DOI":"10.1016\/j.anndiagpath.2019.151412","article-title":"Prevalence and spectrum of T-cell lymphoproliferative disorders in patients with hypereosinophilia: a reference laboratory experience","volume":"44","year":"2020","journal-title":"Ann Diagn Pathol"},{"issue":"15","key":"bib31-20221117","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1056\/NEJM199910073411503","article-title":"Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia","volume":"341","year":"1999","journal-title":"N Engl J Med"},{"issue":"6","key":"bib32-20221117","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.jaip.2015.06.009","article-title":"Hematologic malignancies identified in patients with hypereosinophilia and hypereosinophilic syndromes","volume":"3","year":"2015","journal-title":"J Allergy Clin Immunol Pract"},{"key":"bib33-20221117","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1016\/j.ejim.2016.05.024","article-title":"Frequency of abnormal T-cells in hypereosinophilic syndrome and hypereosinophilia of undetermined significance\u2014extended follow-up","volume":"35","year":"2016","journal-title":"Eur J Intern Med"},{"issue":"4","key":"bib34-20221117","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.jaci.2013.06.037","article-title":"Marked and persistent eosinophilia in the absence of clinical manifestations","volume":"133","year":"2014","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"bib35-20221117","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/ejh.13437","article-title":"Causes of hypereosinophilia in 100 consecutive patients","volume":"105","year":"2020","journal-title":"Eur J Haematol"},{"issue":"11","key":"bib36-20221117","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1002\/ajh.25247","article-title":"A multimodality work-up of patients with hypereosinophilia","volume":"93","year":"2018","journal-title":"Am J Hematol"},{"issue":"3","key":"bib37-20221117","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ejim.2006.09.031","article-title":"Eosinophilia: a study of 100 hospitalized patients","volume":"18","year":"2007","journal-title":"Eur J Intern Med"},{"issue":"6","key":"bib38-20221117","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.jaci.2010.02.024","article-title":"Heterogeneity among characteristics of hypereosinophilic syndromes","volume":"125","year":"2010","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"bib39-20221117","doi-asserted-by":"crossref","first-page":"bcr2018227137","DOI":"10.1136\/bcr-2018-227137","article-title":"Idiopathic hypereosinophilic syndrome with cutaneous involvement: a comparative review of 32 cases","volume":"11","year":"2018","journal-title":"BMJ Case Rep"},{"issue":"24","key":"bib40-20221117","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1056\/NEJMoa031261","article-title":"Use of an anti\u2013interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis","volume":"349","year":"2003","journal-title":"N Engl J Med"},{"issue":"4","key":"bib41-20221117","first-page":"108","article-title":"Idiopathic hypereosinophilic syndrome: a rare cause of erythroderma","volume":"8","year":"2014","journal-title":"J Dermatol Case Rep"},{"issue":"5","key":"bib42-20221117","first-page":"OD15","article-title":"A case of erythroderma secondary to hypereosinophilia","volume":"10","year":"2016","journal-title":"J Clin Diagn Res"},{"issue":"3","key":"bib43-20221117","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1590\/abd1806-4841.20187419","article-title":"Case for diagnosis. Erythroderma as manifestation of hypereosinophilic syndrome","volume":"93","year":"2018","journal-title":"An Bras Dermatol"},{"issue":"8","key":"bib44-20221117","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1001\/jamadermatol.2015.0388","article-title":"Janeway lesions and splinter hemorrhages in a patient with eosinophilic endomyocarditis","volume":"151","year":"2015","journal-title":"JAMA Dermatol"},{"issue":"3","key":"bib45-20221117","doi-asserted-by":"crossref","first-page":"e211","DOI":"10.1111\/ajd.12717","article-title":"Crescentic splinter haemorrhages reflect stroke pathophysiology in hypereosinophilic syndrome","volume":"59","year":"2018","journal-title":"Australas J Dermatol"},{"issue":"3","key":"bib46-20221117","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.iac.2007.07.009","article-title":"Dermatologic manifestations of the hypereosinophilic syndromes","volume":"27","year":"2007","journal-title":"Immunol Allergy Clin North Am"},{"issue":"3","key":"bib47-20221117","first-page":"168","article-title":"Digital gangrene associated with idiopathic hypereosinophilia: treatment with allogeneic cultured dermal substitute (CDS)","volume":"14","year":"2004","journal-title":"Eur J Dermatol"},{"issue":"3","key":"bib48-20221117","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/j.1365-2133.2000.03726.x","article-title":"Hypereosinophilic syndrome presenting as cutaneous necrotizing eosinophilic vasculitis and Raynaud's phenomenon complicated by digital gangrene","volume":"143","year":"2000","journal-title":"Br J Dermatol"},{"issue":"8","key":"bib49-20221117","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.jdcr.2019.06.013","article-title":"Skin-limited idiopathic hypereosinophilic syndrome presenting with retiform purpura","volume":"5","year":"2019","journal-title":"JAAD Case Rep"},{"issue":"3","key":"bib50-20221117","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2340\/00015555-1044","article-title":"Extensive digital gangrene without evidence of large-vessel occlusion in hypereosinophilic syndrome","volume":"91","year":"2011","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"bib51-20221117","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1046\/j.1365-2133.2001.04207.x","article-title":"Digital necrosis in a patient with hypereosinophilic syndrome in the absence of cutaneous eosinophilic vasculitis","volume":"144","year":"2001","journal-title":"Br J Dermatol"},{"issue":"6","key":"bib52-20221117","first-page":"812","article-title":"Hypereosinophilic syndrome with peripheral circulatory insufficiency and cutaneous microthrombi","volume":"143","year":"2007","journal-title":"Arch Dermatol"},{"issue":"3","key":"bib53-20221117","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.jvscit.2017.12.001","article-title":"Hypereosinophilic syndrome complicated by severe vascular damage and gangrene","volume":"5","year":"2019","journal-title":"J Vasc Surg Cases Innov Tech"},{"issue":"4","key":"bib54-20221117","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/j.jaip.2019.12.011","article-title":"\u201cIdiopathic eosinophilic vasculitis\u201d: another side of hypereosinophilic syndrome? A comprehensive analysis of 117 cases in asthma-free patients","volume":"8","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"bib55-20221117","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/1346-8138.15139","article-title":"Rare manifestation of hypereosinophilic syndrome: diffuse-type hair loss with massive perifollicular eosinophils","volume":"47","year":"2020","journal-title":"J Dermatol"},{"issue":"3","key":"bib56-20221117","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/j.1365-2133.2000.03750.x","article-title":"Hypereosinophilic dermatosis: skin lesions as the only manifestation of the idiopathic hypereosinophilic syndrome?","volume":"143","year":"2000","journal-title":"Br J Dermatol"},{"key":"bib57-20221117","first-page":"213","article-title":"Acute pulmonary embolism and deep vein thrombosis secondary to idiopathic hypereosinophilic syndrome","volume":"25","year":"2018","journal-title":"Respir Med Case Rep"},{"issue":"3","key":"bib58-20221117","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.iac.2015.04.002","article-title":"Spectrum of eosinophilic end-organ manifestations","volume":"35","year":"2015","journal-title":"Immunol Allergy Clin North Am"},{"issue":"3","key":"bib59-20221117","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.iac.2007.07.007","article-title":"Clinical overview of hypereosinophilic syndromes","volume":"27","year":"2007","journal-title":"Immunol Allergy Clin North Am"},{"issue":"2","key":"bib60-20221117","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s11239-020-02127-2","article-title":"An unusual presentation of idiopathic hypereosinophilic syndrome","volume":"50","year":"2020","journal-title":"J Thromb Thrombolysis"},{"issue":"2","key":"bib61-20221117","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s11882-012-0241-z","article-title":"Clinical overview of cutaneous features in hypereosinophilic syndrome","volume":"12","year":"2012","journal-title":"Curr Allergy Asthma Rep"},{"issue":"11","key":"bib62-20221117","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1111\/all.14368","article-title":"Medical algorithm: diagnosis and treatment of hypereosinophilic syndrome","volume":"75","year":"2020","journal-title":"Allergy"},{"issue":"2","key":"bib63-20221117","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s12016-015-8485-8","article-title":"Eosinophilic skin diseases: a comprehensive review","volume":"50","year":"2016","journal-title":"Clin Rev Allergy Immunol"},{"issue":"4","key":"bib64-20221117","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1046\/j.1365-2133.2002.49093.x","article-title":"Wells' syndrome as a manifestation of hypereosinophilic syndrome","volume":"147","year":"2002","journal-title":"Br J Dermatol"},{"key":"bib65-20221117","first-page":"201","article-title":"The role of eosinophils in bullous pemphigoid: a developing model of eosinophil pathogenicity in mucocutaneous disease","volume":"5","year":"2018","journal-title":"Front Med (Lausanne)"},{"issue":"5","key":"bib66-20221117","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1111\/bjd.16679","article-title":"Peripheral eosinophilia in bullous pemphigoid: prevalence and influence on the clinical manifestation","volume":"179","year":"2018","journal-title":"Br J Dermatol"},{"issue":"10","key":"bib67-20221117","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1034\/j.1398-9995.2002.23479.x","article-title":"Incidence of peripheral blood eosinophilia and the threshold eosinophile count for indicating hypereosinophilia-associated diseases","volume":"57","year":"2002","journal-title":"Allergy"},{"issue":"6","key":"bib68-20221117","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1398-9995.2004.00476.x","article-title":"Eosinophils and atopic dermatitis","volume":"59","year":"2004","journal-title":"Allergy"},{"issue":"2 suppl case reports","key":"bib69-20221117","first-page":"S157","article-title":"Cutaneous strongyloides stercoralis infection: an unusual presentation","volume":"49","year":"2003","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"bib70-20221117","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/0190-9622(92)70011-4","article-title":"Clinicopathologic spectrum of specific cutaneous lesions of disseminated coccidioidomycosis","volume":"26","year":"1992","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"bib71-20221117","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/bjh.14488","article-title":"Guideline for the investigation and management of eosinophilia","volume":"176","year":"2017","journal-title":"Br J Haematol"},{"issue":"5","key":"bib72-20221117","first-page":"670","article-title":"Persistent eosinophilia as a presenting sign of scabies in patients with disorders of keratinization","volume":"143","year":"2007","journal-title":"Arch Dermatol"},{"issue":"5","key":"bib73-20221117","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jinf.2004.08.033","article-title":"Crusted scabies: clinical and immunological findings in seventy-eight patients and a review of the literature","volume":"50","year":"2005","journal-title":"J Infect"},{"issue":"3","key":"bib74-20221117","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.iac.2014.04.012","article-title":"Management of nonimmediate hypersensitivity reactions to drugs","volume":"34","year":"2014","journal-title":"Immunol Allergy Clin North Am"},{"issue":"7","key":"bib75-20221117","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.amjmed.2011.01.017","article-title":"The DRESS syndrome: a literature review","volume":"124","year":"2011","journal-title":"Am J Med"},{"issue":"6","key":"bib76-20221117","first-page":"31","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome","volume":"6","year":"2013","journal-title":"J Clin Aesthet Dermatol"},{"issue":"5","key":"bib77-20221117","doi-asserted-by":"crossref","first-page":"693.e1","DOI":"10.1016\/j.jaad.2013.01.033","article-title":"DRESS syndrome: part I. Clinical perspectives","volume":"68","year":"2013","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"bib78-20221117","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.alit.2019.03.006","article-title":"Drug-induced hypersensitivity syndrome (DiHS)\/drug reaction with eosinophilia and systemic symptoms (DRESS): an update in 2019","volume":"68","year":"2019","journal-title":"Allergol Int"},{"issue":"5","key":"bib79-20221117","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/liv.14004","article-title":"Drug-induced liver injury with skin reactions: drugs and host risk factors, clinical phenotypes and prognosis","volume":"39","year":"2019","journal-title":"Liver Int"},{"key":"bib80-20221117","first-page":"240","article-title":"Clinical and biological markers in hypereosinophilic syndromes","volume":"4","year":"2017","journal-title":"Front Med (Lausanne)"},{"issue":"8","key":"bib81-20221117","doi-asserted-by":"crossref","first-page":"e348","DOI":"10.3324\/haematol.2017.187302","article-title":"Molecular genetic characterization of myeloid\/lymphoid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, FGFR1 or PCM1-JAK2","volume":"103","year":"2018","journal-title":"Haematologica"},{"issue":"17","key":"bib82-20221117","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/MD.0000000000000088","article-title":"The lymphoid variant of hypereosinophilic syndrome: study of 21 patients with CD3-CD4+ aberrant T-cell phenotype","volume":"93","year":"2014","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"bib83-20221117","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/cyto.b.21874","article-title":"Lymphocytic variant of hypereosinophilic syndrome: a report of seven cases from a single institution","volume":"100","year":"2021","journal-title":"Cytometry B Clin Cytom"},{"issue":"2","key":"bib84-20221117","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1053\/j.seminhematol.2012.01.003","article-title":"Lymphoproliferative disorders associated with hypereosinophilia","volume":"49","year":"2012","journal-title":"Semin Hematol"},{"issue":"3","key":"bib85-20221117","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.jaci.2007.05.024","article-title":"KIT D816V\u2013associated systemic mastocytosis with eosinophilia and FIP1L1\/PDGFRA-associated chronic eosinophilic leukemia are distinct entities","volume":"120","year":"2007","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"bib86-20221117","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jaci.2010.03.042","article-title":"Refining the definition of hypereosinophilic syndrome","volume":"126","year":"2010","journal-title":"J Allergy Clin Immunol"},{"issue":"11","key":"bib87-20221117","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.1182\/blood-2006-10-050054","article-title":"Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA\u2013positive chronic eosinophilic leukemia","volume":"109","year":"2007","journal-title":"Blood"},{"issue":"1","key":"bib89-20221117","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jaip.2020.08.034","article-title":"Successful treatment of idiopathic hypereosinophilic syndrome with benralizumab in a pediatric patient","volume":"9","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"8","key":"bib90-20221117","doi-asserted-by":"crossref","first-page":"e00665","DOI":"10.1002\/rcr2.665","article-title":"Idiopathic hypereosinophilic syndrome in remission with benralizumab treatment after relapse with mepolizumab","volume":"8","year":"2020","journal-title":"Respirol Case Rep"},{"issue":"3","key":"bib91-20221117","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1007\/s10875-020-00946-9","article-title":"Benralizumab in severe and refractory PDGFRA-negative hypereosinophilic syndrome","volume":"41","year":"2021","journal-title":"J Clin Immunol"},{"issue":"4","key":"bib92-20221117","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jdcr.2020.02.030","article-title":"Improvement in a patient with hypereosinophilic syndrome after initiation of dupilumab treatment","volume":"6","year":"2020","journal-title":"JAAD Case Rep"},{"issue":"3","key":"bib93-20221117","doi-asserted-by":"crossref","first-page":"e185","DOI":"10.1016\/j.oooo.2013.03.017","article-title":"Hypereosinophilic syndrome\u2014lymphocytic variant transforming into peripheral T-cell lymphoma with severe oral manifestations","volume":"116","year":"2013","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"issue":"4","key":"bib94-20221117","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.leukres.2012.12.016","article-title":"Mortality in hypereosinophilic syndrome: 19 years of experience at Mayo Clinic with a review of the literature","volume":"37","year":"2013","journal-title":"Leuk Res"},{"issue":"2","key":"bib95-20221117","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1136\/heartjnl-2015-307959","article-title":"Hypereosinophilic syndrome: cardiac diagnosis and management","volume":"102","year":"2016","journal-title":"Heart"}],"container-title":["Dermatitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/DER.0000000000000803","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T18:06:27Z","timestamp":1777399587000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.1097\/DER.0000000000000803"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":93,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/der.0000000000000803","relation":{},"ISSN":["2162-5220","1710-3568"],"issn-type":[{"value":"2162-5220","type":"electronic"},{"value":"1710-3568","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]}}}